Wedmont Private Capital Acquires Shares of 3,231 DexCom, Inc. (NASDAQ:DXCM)

Wedmont Private Capital acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 3,231 shares of the medical device company's stock, valued at approximately $214,000.

Other large investors have also recently added to or reduced their stakes in the company. Private Trust Co. NA lifted its position in shares of DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after buying an additional 245 shares during the last quarter. Optiver Holding B.V. bought a new position in shares of DexCom in the 4th quarter worth about $33,000. TD Private Client Wealth LLC lifted its position in shares of DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after buying an additional 167 shares during the last quarter. Larson Financial Group LLC lifted its position in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after buying an additional 137 shares during the last quarter. Finally, Heck Capital Advisors LLC bought a new position in shares of DexCom in the 4th quarter worth about $38,000. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Down 1.0%

Shares of NASDAQ:DXCM traded down $0.86 during mid-day trading on Friday, hitting $81.99. 2,904,075 shares of the company traded hands, compared to its average volume of 4,350,358. The firm has a market cap of $32.15 billion, a P/E ratio of 57.34, a PEG ratio of 2.30 and a beta of 1.46. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $117.91. The firm's 50 day simple moving average is $78.50 and its 200 day simple moving average is $79.32.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. DexCom's revenue was up 12.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.32 earnings per share. On average, equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Upgrades and Downgrades

DXCM has been the topic of a number of analyst reports. The Goldman Sachs Group assumed coverage on shares of DexCom in a report on Friday, May 30th. They issued a "buy" rating and a $104.00 price objective on the stock. Canaccord Genuity Group lifted their price objective on shares of DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Wall Street Zen upgraded shares of DexCom from a "hold" rating to a "buy" rating in a report on Friday, June 6th. Wells Fargo & Company reiterated an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Finally, Cfra Research upgraded shares of DexCom to a "hold" rating in a report on Friday, March 21st. Four investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $98.32.

Insider Activity at DexCom

In other DexCom news, EVP Michael Jon Brown sold 10,000 shares of the stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $84.28, for a total value of $842,800.00. Following the completion of the sale, the executive vice president now directly owns 95,602 shares in the company, valued at $8,057,336.56. This represents a 9.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Sadie Stern sold 6,184 shares of the stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total value of $526,320.24. Following the transaction, the executive vice president now owns 109,621 shares in the company, valued at approximately $9,329,843.31. This trade represents a 5.34% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 16,536 shares of company stock worth $1,393,876 in the last 90 days. 0.32% of the stock is owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.